Quote | Super Quote
Super Quote   |   Detail Quote   |   Interactive Chart   |   Transaction   |   Related News   |   Related Securities   |   Company Information   |   Dividend Records   |   Short Sell
01558 HEC CJ PHARM
RTNominal up12.680 +0.180 (+1.440%)
Others

28/10/2019 13:45

{I-bank focus}Huatai lifts HEC Pharm (01558) to HK$51.6

[ET Net News Agency, 28 October 2019] Huatai Research lifted its target price for
Yichang HEC Changjiang Pharmaceutical (01558) to HK$51.6 from HK$46.6 and maintained its
"buy" rating.
The research house said HEC Pharma's 1Q-3Q results exceeded Huatai's and consensus
expectations, given Kewei's low base in 3Q 2018 and fast expansion at the grassroots level
and OTC channel in 3Q.
Huatai predicted that the strong net profit growth momentum will continue in 4Q, given a
possible wave of influenza then. Considering the potential catalysts of looser
restrictions on oseltamivir in the 2019 NRDL, and incremental sales from ANDAs/innovative
pipeline (insulin and HCV), Huatai raised its 2019/20/21 EPS forecasts by 12/11/9% to
HK$3.65/4.30/4.85. (KL)

Back to Others

Remark: Real time quote last updated: 26/04/2024 14:09
  Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service
A Member of HKET Holdings
Customer Service Hotline:(852) 2880 7004     Customer Service Email:cs@etnet.com.hk
Copyright 2024 ET Net Limited. http://www.etnet.com.hk ET Net Limited, HKEx Information Services Limited, its Holding Companies and/or any Subsidiaries of such holding companies, and Third Party Information Providers endeavour to ensure the availability, completeness, timeliness, accuracy and reliability of the information provided but do not guarantee its availability, completeness, timeliness, accuracy or reliability and accept no liability (whether in tort or contract or otherwise) any loss or damage arising directly or indirectly from any inaccuracies, interruption, incompleteness, delay, omissions, or any decision made or action taken by you or any third party in reliance upon the information provided. The quotes, charts, commentaries and buy/sell ratings on this website should be used as references only with your own discretion. ET Net Limited is not soliciting any subscriber or site visitor to execute any trade. Any trades executed following the commentaries and buy/sell ratings on this website are taken at your own risk for your own account.